Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Resolutions at the Annual General Meeting in Medivir on 5 May 2022 PR Newswire HUDDINGE, Sweden, May 5, 2022 HUDDINGE, Sweden, May 5, 2022...
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2022 PR Newswire HUDDINGE, Sweden, April 28, 2022 HUDDINGE, Sweden, April 28, 2022 /PRNewswire/...
Medivir to present at the Redeye Orphan Drugs Conference PR Newswire STOCKHOLM, April 25, 2022 STOCKHOLM, April 25, 2022 /PRNewswire/ -- Medivir...
Medivir to participate at the Kempen Life Sciences Conference PR Newswire STOCKHOLM, Sweden, April 19, 2022 STOCKHOLM, Sweden, April 19, 2022...
Medivir 2021 Annual Report published PR Newswire STOCKHOLM, April 5, 2022 STOCKHOLM, April 5, 2022 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm:...
Notice of Annual General Meeting of Medivir AB (publ) PR Newswire HUDDINGE, Sweden, April 4, 2022 HUDDINGE, Sweden, April 4, 2022 /PRNewswire/...
A subgroup analysis of Medivir´s phase II study of MIV-711 for osteoarthritis shows statistically significant reduction in OA pain PR...
Medivir to present at the Erik Penser Bank Health Care Day PR Newswire STOCKHOLM, Feb. 22, 2022 STOCKHOLM, Feb. 22, 2022 /PRNewswire/ -- Medivir...
MEDIVIR AB - YEAR-END REPORT JANUARY - DECEMBER 2021 Significant progress, both in the clinical program and in our business development PR...
Medivir's MIV-818 obtains the International Nonproprietary Name fostroxacitabine bralpamide PR Newswire STOCKHOLM, Jan. 18, 2022 STOCKHOLM, Jan...
Jens Lindberg takes office as CEO of Medivir on January 24 PR Newswire STOCKHOLM, Jan. 17, 2022 STOCKHOLM, Jan. 17, 2022 /PRNewswire/ -- Medivir...
Medivir to present at the H.C. Wainwright BioConnect Virtual Conference PR Newswire STOCKHOLM, Jan. 10, 2022 STOCKHOLM, Jan. 10, 2022...
First patient dosed in the MIV-818 combination study PR Newswire STOCKHOLM, Dec. 14, 2021 STOCKHOLM, Dec. 14, 2021 /PRNewswire/ -- Medivir AB...
Medivir to present at the Erik Penser Bank Life Science Day PR Newswire STOCKHOLM, Dec. 1, 2021 STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Medivir...
Results from investigator-initiated phase II clinical study of remetinostat in patients with squamous cell carcinoma published PR...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지